AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$PK

Park Hotels & Resorts Inc. Stock 12‑Month Price Target Raised to $15.91, Implies 5% Upside

Park Hotels & Resorts Inc. stock's average price target raised to $15.91 by 16 analysts, up from $15.78, with a 5% upside potential. Consensus rating is 'Hold' with 6 Buys, 10 Holds, and 2 Sells.

Original reporting
tradingview.com
Published Oct 12, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Park Hotels & Resorts Inc. Stock 12‑Month Price Target Raised to $15.91, Implies 5% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$PKBullishLow
01

Why it matters

Analyst consensus upgrade signals modest confidence but does not constitute a major catalyst.

02

Market read

The target increase offers a small upside cue for traders but lacks a strong actionable trigger.

03

What to watch

Potential impact of upcoming earnings or macro‑economic shifts not reflected in the target.

Relevance 5/10Novelty 5/10Timing: today

Background

Park Hotels & Resorts is a U.S. REIT focused on upscale hotel properties.

Company-level read

Ticker impact

$PKBullishMedium confidence
Context

Analysts raised the average price target for Park Hotels & Resorts to $15.91, implying about 5% upside.

Expected impact

likely modest upward pressure as investors price in the higher target

Evidence & confidence

The new consensus target is only slightly above the current price, indicating limited but positive impact.

Market effects

Sector

Minimal effect on the hospitality REIT sector; target changes are company‑specific.

Regional

Limited to U.S. REIT investors.

Global

Low

Counterpoint

What could challenge this read

The target raise may be premature if earnings outlook weakens.

Key entities

  • company
    Park Hotels & Resorts Inc.

    U.S.-listed REIT (ticker PK) whose price target was raised.

Read at source← All news

Related articles

AUG 6
$PKLow

Park Hotels & Resorts Inc. Reports Second Quarter 2026 Results

Park Hotels & Resorts Inc. (PK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Contact 1775 Tysons Boulevard, 7th Floor Ian Weissman Tysons, VA 22102 + 1 571 302 5591 www.pkhotelsandresorts.com Park Hotels & Resorts Inc. Reports Second Quarter 2026 Results TYSONS, VA (August 6, 2026) – Park Hotels & Resorts Inc. (“Park” or the “Company

SEC EDGAR 8-K7 min
JUL 17
$PSAMed

REIT ETF RDOG Rides M&A, Refinancing Wave to 22% Gain

RDOG, the ALPS REIT Dividend Dogs ETF, gained 22.1% year to date through July 17, helped by M&A, credit upgrades and refinancings in its holdings. National Storage Affiliates jumped 66.2% after Public Storage agreed to buy it in March. Other contributors included FrontView, Postal Realty and RLJ Lodging. Nareit reported 8 REIT mergers and privatizations worth $57.7B through June.

etftrends.com7 min
OCT 28
$FWRDMed

Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

SEC EDGAR 8-K4 min
OCT 28
$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

investing.com2 min